Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder

Trial Profile

A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2018

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Alcoholism
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 20 Aug 2018 According to a MediciNova media release, that the National Institute on Alcohol Abuse and Alcoholism (NIAAA) will fund this trial. The NIAAA R01 research funding was awarded to Principal Investigator Dr. Lara Ray at the University of California (UCLA) Departments of Psychology, and Psychiatry and Biobehavioral Sciences Brain Research Institute. MediciNova will provide drug supply and regulatory support for the trial.
    • 25 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top